Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study

INTRODUCTION: The optimal number of cycles of adjuvant docetaxel and cyclophosphamide (DC) in patients with node negative breast cancer is not known. We aimed to analyse the survival outcomes of patients with node negative and human epidermal growth factor receptor (HER2)-negative breast cancer trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Batra, Atul, Hannouf, Malek B., Alsafar, Noura, Lupichuk, Sasha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475113/
https://www.ncbi.nlm.nih.gov/pubmed/32861882
http://dx.doi.org/10.1016/j.breast.2020.08.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475113/
https://www.ncbi.nlm.nih.gov/pubmed/32861882
http://dx.doi.org/10.1016/j.breast.2020.08.002

Ejemplares similares